Active substance
Terbinafine
- SFDA 22
- US FDA 25
- Health Canada 8
- US price lines 4
- NHS prices 6
- WHO EML 1
- Safety 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| LAMIFEN 1% CREAM | 1 % | Cream · Topical | 1 Bottle | SAR 19.50 | Generic · OTC | Jamjoom Pharmaceuticals Factory Company | Valid |
| LAMIFEN 250MG TABLET | 250 mg | Tablet · Oral use | 7 Blister | SAR 34.40 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| LAMIFEN 250MG TABLET | 250 mg | Tablet · Oral use | 14 Bottle | SAR 68.85 | Generic · Prescription | Jamjoom Pharmaceuticals Factory Company | Valid |
| LAMISIL 1% CREAM | 1 % | Cream · Topical | 1 Tube | SAR 23.15 | NCE · OTC | GSK CONSUMER HEALTHCARE SCHWEIZ AG | Valid |
| LAMISIL 1% SPRAY | 1 % | Spray · Topical | 1 Bottle | SAR 43.20 | NCE · OTC | GSK CONSUMER HEALTHCARE SCHWEIZ AG | Valid |
| LAMISIL 250 mg tablet | 250 mg | Tablet · Oral use | 14 Blister | SAR 68.85 | NCE · Prescription | NOVARTIS | Valid |
| LAMISIL ONCE 1% CUTANEOUS SOLUTION | 1 % | Solution · Topical | 1 Spray Pump | SAR 26.65 | NCE · OTC | NOVARTIS | Valid |
| NEGAFEN 1% cream | 1 % | Cream · Topical | 1 Tube | SAR 10.95 | Generic · OTC | Gulf Pharmaceutical Industries (Julphar) | Valid |
| NEGAFEN 250 mg tablet | 250 mg | Tablet · Oral use | 14 Blister | SAR 68.85 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| TERFINA CREAM | 1.02 % | Cream · Topical | 1 Tube | SAR 10.95 | Generic · OTC | OMAN PHARMACEUTICAL PRODUCTS | Valid |
| Xeerun | 1 % | Cutaneous spray, solution · Topical | 1 Spray Container | SAR 28.55 | Generic · OTC | Amman Pharmaceutical Industries (API) | Valid |
| LAMISIL 1% SOLUTION | 1 % | Cutaneous solution · Topical | 1 Bottle | SAR 42.70 | NCE · Prescription | NOVARTIS | Withdrawn by MAH · Not Marketed |
| LAMISIL 250 mg tablet | 250 mg | Tablet · Oral use | 28 Blister | SAR 137.70 | NCE · Prescription | NOVARTIS | Withdrawn by MAH · Not Marketed |
| LAMISIL DERM 1% GEL | 1 % | Gel · Topical | 1 Tube | SAR 12.15 | NCE · OTC | NOVARTIS | Withdrawn by MAH · Not Marketed |
| RIATEBIFINE | 250 % | Cream · Topical | 14 Blister | SAR 68.85 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| RIATEBIFINE | 250 mg | Tablet · Oral use | 1 Bottle | SAR 13.50 | Generic · OTC | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| RIATEBIFINE | 250 mg | Tablet · Oral use | 7 Blister | SAR 60.10 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| RIATEBIFINE 1% TOPICAL SOLUTION | 1 % | Cutaneous solution · Topical | 1 Bottle | SAR 29.90 | Generic · OTC | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
| TERBIN 1% CREAM | 1 % | Cream · Topical | 1 Tube | SAR 5.40 | Generic · OTC | GLOBAL NABI | Withdrawn by MAH · Not Marketed |
| TERFINIL 1% CREAM | 1 % | Cream · Topical | 1 Tube | SAR 12.15 | Generic · OTC | Jazeera Pharmaceutical Industries (JPI) | Withdrawn by MAH · Not Marketed |
| TERFINIL 125MG TABLETS | 125 mg | Tablet · Oral use | 14 Blister | SAR 44.25 | Generic · Prescription | Hikma Pharmaceuticals PLC | Withdrawn by MAH · Not Marketed |
| TERFINIL 250MG TABLETS | 250 mg | Tablet · Oral use | 14 Blister | SAR 88.55 | Generic · Prescription | Hikma Pharmaceuticals PLC | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
HUMAN IMMUNODEFICIENCY VIRUS; LICHEN PLANUS; SEBORRHEIC DERMATITIS; TINEA CORPORIS, TINEA CRURIS, AND TINEA PEDIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| LAMISIL | 1% | cream · topical | KARO HLTHCARE | Over-the-counter | 9 Mar 1999 |
| LAMISIL AT | 1% | solution · topical | KARO HLTHCARE | Over-the-counter | 17 Mar 2000 |
| LAMISIL AT | 1% | spray · topical | KARO HLTHCARE | Over-the-counter | 17 Mar 2000 |
| LAMISIL AT | 1% | gel · topical | KARO HLTHCARE | Over-the-counter | 24 Jul 2006 |
| TERBINAFINE HYDROCHLORIDE | EQ 250MG BASE | tablet · oral | SENORES PHARMS | Prescription | 2 Jul 2007 |
| TERBINAFINE HYDROCHLORIDE | EQ 250MG BASE | tablet · oral | CIPLA | Prescription | 2 Jul 2007 |
| TERBINAFINE HYDROCHLORIDE | 1% | cream · topical | SUN PHARMA CANADA | Over-the-counter | 2 Jul 2007 |
| TERBINAFINE HYDROCHLORIDE | EQ 250MG BASE | tablet · oral | EMED MEDCL | Prescription | 2 Jul 2007 |
| TERBINAFINE HYDROCHLORIDE | EQ 250MG BASE | tablet · oral | GLENMARK PHARMS LTD | Prescription | 2 Jul 2007 |
| TERBINAFINE HYDROCHLORIDE | EQ 250MG BASE | tablet · oral | ORBION PHARMS | Prescription | 2 Jul 2007 |
| TERBINAFINE HYDROCHLORIDE | EQ 250MG BASE | tablet · oral | CHARTWELL | Prescription | 2 Jul 2007 |
| TERBINAFINE HYDROCHLORIDE | EQ 250MG BASE | tablet · oral | AUROBINDO PHARMA | Prescription | 2 Jul 2007 |
| LAMISIL | 1% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | cream · topical | NOVARTIS | Discontinued | 30 Dec 1992 |
| LAMISIL | EQ 250MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | tablet · oral | NOVARTIS | Discontinued | 10 May 1996 |
| LAMISIL | 1% | solution · topical | KARO HLTHCARE | Discontinued | 17 Oct 1997 |
| LAMISIL | 1% | gel · topical | KARO HLTHCARE | Discontinued | 29 Apr 1998 |
| TERBINAFINE HYDROCHLORIDE | EQ 250MG BASE | tablet · oral | HERITAGE PHARMA AVET | Discontinued | 2 Jul 2007 |
| TERBINAFINE HYDROCHLORIDE | EQ 250MG BASE | tablet · oral | NATCO PHARMA | Discontinued | 2 Jul 2007 |
| TERBINAFINE HYDROCHLORIDE | EQ 250MG BASE | tablet · oral | INVAGEN PHARMS | Discontinued | 2 Jul 2007 |
| TERBINAFINE HYDROCHLORIDE | EQ 250MG BASE | tablet · oral | WOCKHARDT | Discontinued | 2 Jul 2007 |
| LAMISIL | EQ 125MG BASE/PACKET; EQ 187.5MG BASE/PACKET | granule · oral | NOVARTIS | Discontinued | 28 Sep 2007 |
| TERBINAFINE HYDROCHLORIDE | EQ 250MG BASE | tablet · oral | BRECKENRIDGE PHARM | Discontinued | 4 Jun 2010 |
| TERBINAFINE HYDROCHLORIDE | EQ 250MG BASE | tablet · oral | GEDEON RICHTER USA | Discontinued | |
| TERBINAFINE HYDROCHLORIDE | EQ 250MG BASE | tablet · oral | MYLAN | Discontinued | |
| TERBINAFINE HYDROCHLORIDE | EQ 250MG BASE | tablet · oral | ROXANE | Discontinued |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-TERBINAFINE | 02239893 | 250 MG | TABLET · ORAL | APOTEX INC |
| AURO-TERBINAFINE | 02320134 | 250 MG | TABLET · ORAL | AURO PHARMA INC |
| LAMISIL | 02031094 | 1 % / % | CREAM · TOPICAL | NOVARTIS PHARMACEUTICALS CANADA INC |
| LAMISIL | 02238703 | 1 % / W/W | SPRAY · TOPICAL | NOVARTIS PHARMACEUTICALS CANADA INC |
| PMS-TERBINAFINE | 02294273 | 250 MG | TABLET · ORAL | PHARMASCIENCE INC |
| TERBINAFINE | 02385279 | 250 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| TERBINAFINE-250 | 02242735 | 250 MG | TABLET · ORAL | PRO DOC LIMITEE |
| TEVA-TERBINAFINE | 02254727 | 250 MG | TABLET · ORAL | TEVA CANADA LIMITED |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | TERBINAFINE 1% CREAM | $0.23063 | per GM | 23 Sep 2026 |
| US NADAC | TERBINAFINE 1% CREAM | $0.39833 | per GM | 23 Sep 2026 |
| US NADAC | TERBINAFINE 1% CREAM | $0.30853 | per GM | 23 Sep 2026 |
| US NADAC | TERBINAFINE HCL 250 MG TABLET | $0.1426 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Terbinafine 1% cream | £1.62 | 15 gram | 1 Oct 2026 |
| NHS Drug Tariff | Terbinafine 1% cream | £3.24 | 30 gram | 1 Oct 2026 |
| NHS Drug Tariff | Terbinafine 1% gel | £4.18 | 15 gram | 1 Oct 2026 |
| NHS Drug Tariff | Terbinafine 1% solution | £6.70 | 4 gram | 1 Oct 2026 |
| NHS Drug Tariff | Terbinafine 1% spray | £4.18 | 15 ml | 1 Oct 2026 |
| NHS Drug Tariff | Terbinafine 250mg tablets | £1.20 | 14 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 13.1. Dermatological medicines > Antifungal medicines · core
Fungal infection of the skin
Local > Topical > Cream: 1% terbinafine hydrochloride | Local > Topical > Ointment: 1% terbinafine hydrochloride
Safety signals and safety-related labeling changes
- US FDA 29 Mar 2019 LAMISIL — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 29 Mar 2019 LAMISIL — safety-related labeling change
Labeling sections changed: Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.